This study investigates the features of severe asthma patients who achieve clinical remission (CtR) after treatment with anti-IL5/IL5r monoclonal antibodies. The study included 266 patients with severe eosinophilic asthma (SEA) treated with Mepolizumab or Benralizumab for 12 months. Patients were classified as in CtR if they showed no exacerbations, no oral corticosteroid (OCS) use, an Asthma Control Test (ACT) score ≥ 20, and a forced expiratory volume in one second (FEV1) ≥ 80% after one year. Key findings include: - 30.5% of patients achieved CtR. - CtR patients had fewer baseline asthma exacerbations and better lung function parameters, with higher ACT scores and less frequent positive skin prick tests. - Factors predicting CtR included better baseline lung function, higher blood eosinophil count, chronic rhinosinusitis with nasal polyps, and less frequent use of reliever therapy. - Higher BMI, positive skin prick test, more asthma exacerbations before treatment, anti-muscarinic administration, and previous diagnosis of EGPA, bronchiectasis, or osteoporosis were negative predictors of CtR. The study highlights the importance of baseline clinical, functional, and biological features in predicting CtR, providing a detailed profile for clinicians to tailor treatment strategies.This study investigates the features of severe asthma patients who achieve clinical remission (CtR) after treatment with anti-IL5/IL5r monoclonal antibodies. The study included 266 patients with severe eosinophilic asthma (SEA) treated with Mepolizumab or Benralizumab for 12 months. Patients were classified as in CtR if they showed no exacerbations, no oral corticosteroid (OCS) use, an Asthma Control Test (ACT) score ≥ 20, and a forced expiratory volume in one second (FEV1) ≥ 80% after one year. Key findings include: - 30.5% of patients achieved CtR. - CtR patients had fewer baseline asthma exacerbations and better lung function parameters, with higher ACT scores and less frequent positive skin prick tests. - Factors predicting CtR included better baseline lung function, higher blood eosinophil count, chronic rhinosinusitis with nasal polyps, and less frequent use of reliever therapy. - Higher BMI, positive skin prick test, more asthma exacerbations before treatment, anti-muscarinic administration, and previous diagnosis of EGPA, bronchiectasis, or osteoporosis were negative predictors of CtR. The study highlights the importance of baseline clinical, functional, and biological features in predicting CtR, providing a detailed profile for clinicians to tailor treatment strategies.